FMEA.

Validation Online has taken the difficulty out of using a Fault Mode Evaluation & Analysis (FMEA) as a method of analysing risk. All the risk assessment tables are included and referenced resdy for use. An analysis flow chart is included to ensure that the overall process is easy to follow and the actual fault analysis spread sheet is expandable to what ever size is required. All complexity has been removed and the this analysis tool can be used by first timers or experts with equal ease.

Try it, and find out just how good an FMEA can be at assisting you to anticipate problems and then pre-empt them through risk mitigation . This document carries our usual warranty; so if you find it unfit for purpose, your purchase costs will be refunded in full.

Once you start using this method of measuring risk, you really will wonder how you managed before. Regulatory agencies world wide now require documented evidence that processes and techniques have been subjected some form of risk analysis.

CLICK HERE TO PURCHASE FMEA DOCUMENT

Failure Mode and Effects Analysis is a model used to identify and prioritize potential defects based on their severity, expected frequency, and likelihood of detection. An FMEA can be performed on a design, an intended design, an individual process or a complete production process. It is used to prompt actions to improve design or process robustness. The FMEA highlights weaknesses in the current design or process in terms of the customer, and is an excellent vehicle to prioritize and organize continuous improvement efforts on areas which offer the greatest return. The VRA should be used to set the scope in validation of the Installation Qualification (IQ), the Operational Qualification (OQ), the Performace Qualification (P1Q) and the Process Qualification (P2Q).

This schematic shows the FMEA flow chart.

The FMEA document is simply excellent for bio-med processes, since it demands that every aspect of the process is reviewed; while accepting and anticipating the fact that things do go wrong. Once this concept is accepted you can probe further by enquiring, what goes wrong, how often does it go wrong and can we pre-empt it going wrong? Further to this we can then analysis; whether a fault will be detrimental to product quality. This knowledge can then be use to devise methods for protecting the product.

If a fault does not readily manifest itself, do we really have to let it destroy the product, or can we build in product protection? The execution of an FMEA provokes thought about these things and stimulates activities that can and do lead to much more robust processes.

Percent Reduction in RPN

The very point of using the FMEA analysis is that on completion of the initial assessment, if the risks are found to be excessive, then there is a bases to proceed in investigating methods of reducing the these risks to acceptable levels. In some cases, it may be appropriate to revise the initial risk assessment based on the assumption (or the fact) that the recommended actions have been completed. This provides an indication of the effectiveness of corrective actions and can also be used to evaluate the value to the organization of performing the FMEA. To calculate revised RPNs, the analysis team assigns a second set of Severity, Occurrence and Detection ratings for each issue (using the same rating scales) and multiplies the revised ratings to calculate the revised RPNs. If both initial and revised RPNs have been assigned, the percent reduction in RPN can also be calculated.

If the initial ratings (1) for a potential problem are S = 7, O = 8 and D = 5 and the ratings post any mitigating actions are S = 7, O = 6 and D = 4, then the percent reduction in RPN from the original to the revised is (280-168)/280) × 100, or 40%. This indicates that the organization was able to reduce the risk associated with the issue by 40% through the performance of the FMEA and the implementation of corrective or mitigating actions.

Risk Assessed	Severity	Occurrence	Detection	RPN
Initial	7	8	5	280
Reworked	7	6	4	168
Percentage Reduction in REN				40%

VRA or FMEA?

Risk Assessment (RA) in the pharmaceutical / biotech / medical device industry, is often misunderstood. In the industry in general RA’s are used at various stages in the product development, production and in testing. Practically always to assure that the product or equipment is robust and fit for purpose.

Generally in these tasks there are many ways of mitigating risk. Whether it is by adjust design parameters, introducing controls or retraining staff, sometimes the choice is endless.

In validation this range of solutions are not there. There are regulatory requirements about documenting justifications, and requirements for critical and none critical software; but not a lot more.

So it actually makes sense to appraise this task in a reverse order; and start with what degree of validation can we define with reasonable accuracy. It becomes apparently that we have not got an infinite variety. Certainly not one we could easily define. So what do we have?

No Validation

Simple validation, basically registering the equipment.

Standard Validation.

Full Life Cycle Validation.

If we use the likes of an Faulure Mode & Effect Analysis we will have a cumbersome analysis result that becomes difficult to use to attribute the correct degree of validation. If we develop a Validation Risk Assessment that only has four outcomes; we can match these outcomes to the four requirements detailed above.

This is the method Validation Online has adopted and used for many years now. The regulators want to see a documented justification for the scope of validation that you have applied, and they require a documented judgement about 21 CFR Part 11, applicability. These requirements are satisfied in our Validation Risk Assessment, where the risk being mitigated is the risk of not being compliant with the regulatory requirements.

FMEA

FMEA FOR BIO-MED USE.

INTRODUCTION & USE OF FMEA

Percent Reduction in RPN

VRA or FMEA?